Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Oct 18, 2025--

Aurion Biotech , a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced positive 12 month results from the company’s Phase 1/2 CLARA trial, which evaluated the safety, efficacy and tolerability of AURN001 (neltependocel [human corneal endothelial cells] in combination with Y-27632 rho-kinase inhibitor) in patients with corneal edema secondary to corneal endothelial dysfunction. The findings were presented at Cornea Day during the American Academy of Ophthalmology (AAO) meeting in Orlando, FL.

In this Phase 1/2 double-masked, parallel-arm, dose-ranging study ( NCT06041256 ), patients treated with a single dose of AURN001 corneal endothelial cell (CEC) th